Cardiac Cell Therapy: Are There Easier Ways to Restore Function? Probably

  
Generate a summary of this article
Listen to this article
Beta

Discussions at the Transcatheter Cardiovascular Therapeutics meeting reinforced the notion that too little is known about cardiac cell therapy to usefully proceed with large-scale studies. Some suggested it'd be more useful to focus on small-molecule or device-oriented approaches to restoring contractile function.

The first ever controlled clinical trials of cardiac cell therapies have yielded only equivocal results: some showed marginal success, others either disappointed or failed outright. A provocative discussion among thought leaders at the October 2006 Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC, reinforced the notion that too little is known about which cell types, doses, and administration routes are most feasible in order to usefully proceed with large-scale studies. A few experts went so far as to suggest eschewing this difficult therapy entirely, in favor of small-molecule or device-oriented approaches to restoring contractile function in the heart—the goal of treatment.

The results of two European trials were most troubling. Previously reported early results from the randomized BOOST study at the...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By Saba Afreen

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

XXXXtesting

 
• By Saba Afreen

XXXXtesting

In Vivo’s 2026 Rising Leaders At A Glance

 
• By Saba Afreen

Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.

InVivo-Innovation-Free: ‘Interview’ article that includes different Composer content

 
• By Nabil, Olga Zviezdicheva, Reed Miller, Mary Jo Laffler, Ian Schofield, João Andrés-Ruíz de la Fontaine-LeBlanc, Chloë Anastasía-Stojanović del Castillo-Ribeirão, and Nabil

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.